BN 52021: A Platelet Activating Factor Antagonist for Preventing Post-Transplant Renal Failure: A Double-Blind, Randomized Study
Authors: Josep M. Grino
Journal: Annals of Internal Medicine (1994)

Brief Communications1 September 1994BN 52021: A Platelet Activating Factor Antagonist for Preventing Post-Transplant Renal Failure: A Double-Blind, Randomized StudyJosep M. GrinoJosep M. GrinoFrom the Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.For The BN 52021 Study Group in Renal Transplantation**Members of the BN 52021 Study Group in Renal Transplantation are listed in the Appendix.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-5-199409010-00006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Platelet activating factor (a glycerophospholipid) is an inflammatory mediator that plays an important role in allergic and inflammatory processes [1], including ischemic renal failure [2-4]. Ginkgolide BN 52021 is a receptor antagonist for platelet activating factor that exerts a protective effect on renal function in experimental ischemic acute renal failure [5]. Many of the pathophysiologic responses and the microcirculatory failure that result from release of platelet activating factor mimic the responses observed after ischemia and reperfusion injury [6]. For example, selectins, integrins, and platelet activating factor contribute to the adhesion of polymorphonuclear cells to the endothelium [7]. We did a ...References1. Braquet P, Rola-Pleszczynski M. Platelet-activating factor and cellular immune responses. Immunol Today. 1987; 11:345-52. Google Scholar2. Pirotzky E, Bidault J, Burtin C, Gubler MC, Benveniste J. Release of platelet activating factor, slow reacting substance and vasoactive amines from isolated rat kidneys. Kidney Int. 1984; 25:404-10. Google Scholar3. Lopez-Farre A, Torralbo M, Lopez-Novoa JM. Glomeruli from ischemic rat kidneys produce increased amounts of platelet activating factor. Biochem Biophys Res Commun. 1988; 152:129-35. Google Scholar4. Schlondorff D, Neuwirth R. Platelet-activating factor and the kidney. Am J Physiol. 1986; 251:F1-F11. Google Scholar5. Torras J, Bordalba JR, Seron D, Moliner R, Carrera M, Valles J, et al. Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. Transpl Int. 1993; 6:236-8. Google Scholar6. Ontell SJ, Makowka L, Boccagni P, Starzl TE. The role of PAF and its antagonism in transplantation: Organ ischemia and preservation. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, eds. Platelet-Activating Factor in Endotoxin and Immune Diseases. New York: Marcel Dekker, Inc; 1990:419-47. Google Scholar7. Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cells interactions with granulocytes: tethering and signaling molecules. Immunol Today. 1992; 13:93-100. Google Scholar8. Grino JM, Castelao AM, Seron D, Gonzalez C, Galceran JM, Gil-Vernet S, et al. Antilymphocyte globulin versus OKT3 induction therapy in kidney cadaveric kidney transplantation: a prospective randomized study. Am J Kidney Dis. 1992; 20:603-10. Google Scholar9. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. Br Med J. 1988; 296:1454-6. Google Scholar10. Conte JV Jr, Katz NM, Wallace RB, Foegh ML. Long-term lung preservation with the PAF antagonist BN 52021. Transplantation. 1991; 51:1152-6. Google Scholar Author, Article, and Disclosure InformationAuthors: Josep M. GrinoAffiliations: From the Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.For The BN 52021 Study Group in Renal Transplantation**Members of the BN 52021 Study Group in Renal Transplantation are listed in the Appendix.Corresponding Author: Josep M. Grino, MD, Department of Nephrology, Hospital de Bellvitge, C. Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byReport of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung TransplantationMesenchymal Stromal Cells for Acute Renal InjuryMesenchymal Stem Cells in Kidney RepairMesenchymal Stem Cells and Their Use in Acute Renal InjuryStem cells and kidney regenerationHuman Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in MiceInsulin-Like Growth Factor-1 Sustains Stem Cell–Mediated Renal RepairRenal transplantation from extended criteria cadaveric donors: problems and perspectives overviewSequential systemic platelet-activating factor and interleukin 8 primes neutrophils in patients with trauma at risk of multiple organ failureReport of the ISHLT Working Group on Primary Lung Graft Dysfunction Part VI: TreatmentQuels sont les mécanismes d'agression rénale sur lesquels il est possible d'intervenir ?Quelles sont les interventions thérapeutiques permettant d'assurer une protection de la fonction rénale ?Lung preservationEmerging drugs for renal failureIschemia–Reperfusion–induced Lung InjuryOliguriaProtective effect of UR‐12670 on chronic nephropathy induced by warm ischaemia in ageing uninephrectomized ratsTratamiento de la necrosis tubular agudaCOLD ISCHEMIA IN THE ABSENCE OF ALLOREACTIVITY INDUCES CHRONIC TRANSPLANT NEPHROPATHY THROUGH A PROCESS MEDIATED BY THE PLATELET-ACTIVATING FACTOR1Borderline kidney graft donors—what are the problems?Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized ratsPotential role of platelet activating factor in acute renal failureManagement of nephrotoxic drugsStrategies to minimize nephrotoxicity associated to calcineurin inhibitorsA GOOD ALTERNATIVE TO REDUCE THE KIDNEY SHORTAGEPharmacological intervention to decrease ischemia-reperfusion injuryAcute renal failure in children and newborns: pathophysiology, clinical patterns and therapeutic approachReperfusion injuryAcute Renal FailureProphylaxis and Conservative Management of Acute Renal Failure in the ICUBB-882 is a Potent Antagonist of the Haemodynamic Changes Induced by Platelet-Activating Factor in PigsPlatelet-Activating Factor 1 September 1994Volume 121, Issue 5Page: 345-347KeywordsCreatinineDrugsImmunosuppressivesKidneysPlateletsRenal failureRenal transplantationReperfusionSurgeryTransplantation ePublished: 15 August 2000 Issue Published: 1 September 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...